DDInter231 DDInter1082
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Brexpiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Brexpiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Brexpiprazole {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Brexpiprazole {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Brexpiprazole may lead to a major life threatening interaction when taken with Bupropion
Brexpiprazole may lead to a major life threatening interaction when taken with Fedratinib